(3S,4R)-4-Methylbenzyl 3-fluoro-4-((pyrimidin-2-ylamino) methyl) piperidine-1-carboxylate (MK-0657) was developed as a highly potent NR2B antagonist (IC50 = 3.6 nM) for the treatment of neuropathic pain, Parkinson's disease, and major depression [17, 62]. Here, GRIN2B is linked to Parkinson disease.